NCT06900686Completed
Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival
A Retrospective Study of the Effect of PD-1 Inhibitors in Improving Clinical Outcome for Colorectal Cancer.
Source: ClinicalTrials.gov · Last updated 28 Mar 2025
Brief summary (registry, in English)
This trial is a single-center retrospective study. Eligible patients receiving PD-1 inhibitor treatment will enrolled.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 458 (actual)
- First submitted
- 23 Mar 2025
- Start date
- 20 Mar 2013
- Primary completion date
- 20 Sept 2022
- Lead sponsor
- Yanhong Deng
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT06900686
What you commit to
- Study type: Observational
- Participants enrolled: 458
- From 20 Mar 2013 to the primary completion date, 20 Sept 2022
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or concurrent cancer that is distinct in primary site or histology from colon cancer within 5 years before randomization.
- Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment.
- Heart failure grade III/IV (NYHA classification). Unresolved toxicity higher than CTCAE v.5.0 Grade 1 attributed to any prior therapy/procedure.
- Subjects with known allergy to the study drugs or any of its excipients. Current or recent (within 4 weeks before starting study treatment) treatment of another investigational drug or participation in another investigational study.
Other
- Breast-feeding or pregnant women Lack of effective contraception.
Who the study is looking for
- Willing and able to provide written informed consent. Histological or cytological documentation of adenocarcinoma of the colorectal. Eastern Cooperative Oncology Group's (ECOG) performance status of 0 or 1. CT or MRI scans (done within 30 days of registration) of the chest, abdomen, and pelvis all without clear evidence of distant metastatic (M1) disease.
- No clinically significant obstruction, perforation, or bleeding related to the primary tumor.
- No previous systemic anticancer therapy for colon cancer disease. Adequate bone marrow, hepatic, and renal function as assessed by the following laboratory requirements conducted within 7 days of starting the study treatment
Criteria the registry did not label
- :
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.